Biotech Values

[exwannabe]

Re: Forbes and DNDN

On the "how does it improve OS and not PFS" question, this was also Dr Scher's (?) position at the AC (and in his letter).

And I always considered it absurd.

The data said Provenge most likely does slow progression (just not stat sig on the metric used).

As a side point, with N = 500 we will likely hit SS in the PFS secondary.

Is that why the Forbes artical has added the "counting deaths" talking point?